CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 4.9% – Should You Buy?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares traded up 4.9% during mid-day trading on Friday . The company traded as high as $4.70 and last traded at $4.6350. 790,139 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 6,510,745 shares. The stock had previously closed at $4.42.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Oppenheimer restated an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a research note on Monday, March 16th. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $7.00 to $12.00 in a research note on Monday, March 16th. Barclays lifted their price objective on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Weiss Ratings downgraded shares of CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, March 19th. Finally, Wedbush upped their target price on shares of CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.44.

CytomX Therapeutics Trading Up 2.3%

The company’s 50-day simple moving average is $5.27 and its 200 day simple moving average is $4.21. The stock has a market cap of $769.26 million, a P/E ratio of -113.00 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. Research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Yu-Waye Chu sold 21,279 shares of CytomX Therapeutics stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $136,611.18. Following the sale, the insider directly owned 189,446 shares in the company, valued at $1,216,243.32. The trade was a 10.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christopher Ogden sold 19,323 shares of CytomX Therapeutics stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the sale, the chief financial officer owned 296,948 shares in the company, valued at $1,906,406.16. The trade was a 6.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 191,063 shares of company stock worth $1,226,624 in the last ninety days. Company insiders own 6.60% of the company’s stock.

Institutional Trading of CytomX Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics in the third quarter worth about $25,000. Wells Fargo & Company MN grew its position in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares during the period. Invesco Ltd. purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $32,000. Pursue Wealth Partners LLC purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.